Home > News > Biophan Names John Lanzafame President of New Nanolution Division
September 16th, 2004
Biophan Names John Lanzafame President of New Nanolution Division
Biophan Technologies, Inc., a developer of next-generation biomedical technology, has appointed biotechnology executive John Lanzafame to serve as president of the Company's Nanolution division, according to Biophan CEO Michael Weiner.
As Nanolution president, Mr. Lanzafame will oversee Biophan's development of advanced nanotechnology-based drug delivery devices and drug-elution technologies, patents, and products.
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
SEMATECH Names William R. Rozich Chairman of the Board June 13th, 2013
David Neuschuler Joins RASIRC to Manage Engineering June 3rd, 2013
Asylum Research Announces Ben Ohler as AFM Business Manager May 29th, 2013